{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:23:17Z","timestamp":1787304197095,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01 DK133118"],"award-info":[{"award-number":["R01 DK133118"]}]},{"award":["R01 DK133118"],"award-info":[{"award-number":["R01 DK133118"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003661","name":"KIAT","doi-asserted-by":"crossref","award":["2410008128"],"award-info":[{"award-number":["2410008128"]}],"id":[{"id":"10.13039\/501100003661","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Burroughs Welcome Fund","award":["1021868.01"],"award-info":[{"award-number":["1021868.01"]}]},{"award":["1021868.01"],"award-info":[{"award-number":["1021868.01"]}],"id":[{"id":"https:\/\/ror.org\/01d35cw23","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure, but the mechanisms remain incompletely understood. Metabolic remodeling has been proposed as a key mediator. Methods and Results: Myocardial infarction (MI) was induced in cardiomyocyte-specific BDH1 knockout (BDH1-KO) wild-type (WT) mice and in liver-specific Fibroblast Growth Factor-21 knockout (FGF21-KO) mice. Following confirmation of reduced ejection fraction (EF), mice were randomized to empagliflozin (Empa, 10 mg\/kg\/day) or saline. After 4 weeks, untreated WT mice demonstrated progressive systolic dysfunction (\u0394EF: \u221211.6 \u00b1 6.3%), whereas Empa-treated WT mice showed significant improvement (\u0394EF: 9.9 \u00b1 4.3%). This benefit was completely abolished in BDH1-KO mice (\u0394EF: \u221210.5 \u00b1 2.8%) or FGF21-KO mice, suggesting that FGF21 regulation and cardiomyocyte ketone oxidation are required for Empa cardioprotection. In WT and hepatocyte-specific FGF21-KO mice, 1 week of Empa treatment increased cardiac BDH1 expression in WT but not FGF21-deficient mice. In human iPSC-cardiomyocytes, FGF21 induced BDH1 expression, whereas Empa had no direct effect on BDH1. In HepG2 liver cells, Empa increased both FGF21 and BDH1 expression. Conclusions: Empa activates the liver\u2013heart metabolic axis. Loss of cardiomyocyte BDH1 or FGF21 production by the liver abolishes Empa-mediated improvement in post-MI cardiac function, identifying FGF21\/ketone metabolism as a key mechanism of SGLT2 inhibitor cardioprotection.<\/jats:p>","DOI":"10.3390\/cells15161478","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:08:41Z","timestamp":1787040521000},"page":"1478","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin Improves Post-Infarct Heart Failure Through Fibroblast Growth Factor-21 and Ketone Body Oxidation Pathway"],"prefix":"10.3390","volume":"15","author":[{"given":"Dao-Fu","family":"Dai","sequence":"first","affiliation":[{"name":"Cardiovascular and Renal Pathology Division, Department of Pathology, School of Medicine, Johns Hopkins University, 632E Ross Building, 720 Rutland Ave, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Martins","sequence":"additional","affiliation":[{"name":"Abboud Cardiovascular Research Center, Department of Internal Medicine, Division of Cardiovascular Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Daneshgar","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gao","sequence":"additional","affiliation":[{"name":"Cardiovascular and Renal Pathology Division, Department of Pathology, School of Medicine, Johns Hopkins University, 632E Ross Building, 720 Rutland Ave, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Mabood","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-952X","authenticated-orcid":false,"suffix":"Jr.","given":"Antentor","family":"Hinton","sequence":"additional","affiliation":[{"name":"Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-4426","authenticated-orcid":false,"given":"Peter A.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Medicine, and Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-742X","authenticated-orcid":false,"given":"Chad","family":"Grueter","sequence":"additional","affiliation":[{"name":"Abboud Cardiovascular Research Center, Department of Internal Medicine, Division of Cardiovascular Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA"},{"name":"Fraternal Order of Eagles Diabetes Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the Management of Cardiovascular Disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tao, Y., Zhang, N., Wang, Z., Pan, Y., Zhong, S., and Liu, H. (2025). SGLT2 Inhibitors Confer Cardiovascular Protection via the Gut-Kidney-Heart Axis: Mechanisms and Translational Perspectives. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12120471"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice","volume":"4","author":"Planavila","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41374-021-00680-9","article-title":"Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice","volume":"102","author":"Yano","year":"2022","journal-title":"Lab. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Feraco, A., Gorini, S., Armani, A., Camajani, E., Rizzo, M., and Caprio, M. (2021). Exploring the Role of Skeletal Muscle in Insulin Resistance: Lessons from Cultured Cells to Animal Models. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179327"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e12313","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/MCB.01085-10","article-title":"Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy","volume":"31","author":"Ellis","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e011980","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","article-title":"Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction","volume":"17","author":"Selvaraj","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The Failing Heart Relies on Ketone Bodies as a Fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCRESAHA.110.223925","article-title":"A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse","volume":"107","author":"Gao","year":"2010","journal-title":"Circ. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-024-02540-4","article-title":"Impact of sodium\u2013glucose cotransporter-2 inhibitors in patients with recent versus previous myocardial infarction: A systematic review and meta-analysis","volume":"24","author":"Scardini","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ejhf.3633","article-title":"Myocardial ketone body oxidation contributes to empagliflozin-induced improvements in cardiac contractility in murine heart failure","volume":"27","author":"Voorrips","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Su, S., Ji, X., Li, T., Teng, Y., Wang, B., Han, X., and Zhao, M. (2023). The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1291450"},{"key":"ref_19","first-page":"1","article-title":"SGLT2 Inhibitors and Ketone Metabolism in Heart Failure","volume":"11","author":"Voorrips","year":"2022","journal-title":"J. Lipid Atheroscler."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106448","DOI":"10.1016\/j.phrs.2022.106448","article-title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes","volume":"184","author":"Marfella","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molmet.2013.12.003","article-title":"Inventing new medicines: The FGF21 story","volume":"3","author":"Kharitonenkov","year":"2014","journal-title":"Mol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.cmet.2025.05.011","article-title":"FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression","volume":"37","author":"Gliniak","year":"2025","journal-title":"Cell Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1540267","DOI":"10.1155\/2016\/1540267","article-title":"Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases","volume":"2016","author":"Cheng","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tillman, E.J., and Rolph, T. (2020). FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.601290"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/cvr\/cvad157","article-title":"Empagliflozin improves cardiac energetics during ischaemia\/reperfusion by directly increasing cardiac ketone utilization","volume":"119","author":"Chase","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/16\/1478\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:25:38Z","timestamp":1787300738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/16\/1478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":29,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15161478"],"URL":"https:\/\/doi.org\/10.3390\/cells15161478","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}